• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Vapotherm Inc. (Amendment)

    9/20/23 6:30:48 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care
    Get the next $VAPO alert in real time by email
    SC 13D/A 1 d520472dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Vapotherm, Inc.

    (Name of Issuer)

    Common Stock, $0.001 Par Value

    (Title of Class of Securities)

    922107 10 7

    (CUSIP Number)

    Joseph F. Army

    President and Chief Executive Officer

    Vapotherm, Inc.

    100 Domain Drive

    Exeter, New Hampshire 03833

    (603) 658-0011

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    September 7, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box:

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedules, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     

     

     


    CUSIP NO. 922107 30 5    SCHEDULE 13D    Page 2 of 7

     

      1    

      Name of Reporting Persons:

     

      Joseph F. Army

      2  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☐

     

      3  

      SEC Use Only

     

      4  

      Source of Funds

     

      PF

      5  

      Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned by

    each

    Reporting

    Person

    with:

     

         7     

      Sole Voting Power

     

      493,393

         8   

      Shared Voting Power

     

      40,717

         9   

      Sole Dispositive Power

     

      493,393

       10   

      Shared Dispositive Power

     

      40,717

    11    

      Aggregate Amount Beneficially Owned By Each Reporting Person

     

      534,110

    12  

      Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares

     

    13  

      Percent of Class Represented by Amount in Row (11)

     

      8.6%

    14  

      Type of Reporting Person:

     

      IN

     

    (1)

    Includes: (a) 390,942 shares of common stock held directly by the reporting person; (b) 42,928 shares of common stock issuable upon exercise of stock options within 60 days of September 14, 2023; (c) 59,523 shares of common stock issuable upon exercise of a warrant; (d) 40,625 shares of common stock held by the Kimberly D. Army Revocable Trust; and (e) 62 shares of common stock and 30 shares of common stock issuable upon exercise of stock options within 60 days of September 14, 2023 held by the reporting person’s spouse.

     

    Page 2 of 7


    EXPLANATORY NOTE

    This Amendment No. 1 to Schedule 13D (this “Amendment No. 1”) hereby amends and supplements a Schedule 13D dated November 28, 2022 (the “Original Statement”),

    Except as set forth below, there are no changes to the information in the Original Statement. All terms used but not defined in this Amendment No. 1 are as defined in the Original Statement. The summary descriptions contained herein of certain agreements and documents are qualified in their entirety by reference to the complete text of such agreements and documents filed as Exhibits hereto or incorporated herein by reference.

    All numbers have been adjusted to reflect a one-for-eight reverse stock split of VAPO’s common stock effective August 18, 2023.

     

    Item 3.

    Source and Amount of Funds or Other Consideration.

    From August 11, 2023 through September 8, 2023, the Reporting Person purchased an aggregate of 187,498 shares of VAPO common stock in open market transactions as follows:

     

    Date of Purchase

       Number of Shares
    Purchased
         Average Price per
    Share
         Total Purchase Price  
    August 11, 2023      27,109        $3.1136      $ 84,407  
    August 14, 2023      2,742        $3.196      $ 8,763  
    August 15, 2023      7,647        $3.3592      $ 25,688  
    August 18, 2023      7,489        $3.0736      $ 23,018  
    August 21, 2023      27,604        $3.6242      $ 100,042  
    August 22, 2023      14,907        $3.9847      $ 59,400  
    September 7, 2023      21,987        $3.3091      $ 72,757  
    September 8, 2023      28,013        $3.4325      $ 96,155  
    September 8, 2023      50,000        $3.5816      $ 179,080  

    TOTAL

         187,498         $ 649,310  

    The source and amount of funds used by the Reporting Person to acquire these additional shares were personal funds in the amount of approximately $650,000.

    On February 10, 2023, the Reporting Person purchased 59,523 shares of VAPO common stock and a warrant to purchase 59,523 shares of VAPO common stock at an exercise price of $9.36 per share in a private placement. The purchase price of this transaction was $8.40 per unit and the source and amount of funds used by the Reporting Person to acquire these additional shares were personal funds in the amount of approximately $500,000.

     

    Page 3 of 7


    Item 4.

    Purpose of Transaction.

    The purchases from February 10, 2023 to September 8, 2023 by the Reporting Person were purchased for general investment purposes. The Reporting Person and immediate family members and related entities of the Reporting Person may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of VAPO common stock or other securities of VAPO or engage in discussions with VAPO concerning further acquisitions of shares of VAPO common stock or other securities of VAPO or further investments in VAPO. The Reporting Person intends to review his investment in VAPO on a periodic basis and, depending upon the price and availability of shares of VAPO common stock or other securities of VAPO, subsequent developments affecting VAPO, VAPO’s business and prospects, other investment and business opportunities available to the Reporting Person, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of his investment in VAPO.

    In addition, from time to time, the Reporting Person and his spouse who is also an employee of VAPO, may acquire beneficial ownership of additional shares of VAPO common stock or other securities of VAPO as compensation from VAPO, including, including, but not limited to, options to purchase shares of VAPO common stock, restricted stock units covering shares of VAPO common stock, performance stock units covering shares of VAPO common stock or other stock awards of shares of VAPO common stock.

    Except as otherwise provided in this Item 4 and other than as to matters that the Reporting Person as a director and officer of VAPO may consider and discuss with other VAPO board members and officers from time to time, the Reporting Person is not aware of any present plans or proposals, which relate to or would result in:

     

      •  

    the acquisition by any person of additional securities of VAPO or the disposition of securities of VAPO;

     

      •  

    an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving VAPO;

     

      •  

    a sale or transfer of a material amount of assets of VAPO;

     

      •  

    any change in the present board of directors or management of VAPO, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

     

      •  

    any material changes in the present capitalization or dividend policy of VAPO;

     

      •  

    any other material changes in VAPO’s business or corporate structure;

     

      •  

    changes in VAPO’s certificate of incorporation, bylaws or instruments corresponding thereto or other actions, which may impede the acquisition of control of VAPO by any person;

     

      •  

    causing a class of securities of VAPO to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

     

      •  

    a class of equity securities of VAPO becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or

     

      •  

    any action similar to any of those listed above.

     

    Page 4 of 7


    Item 5.

    Interest in Securities of the Issuer.

    (a) 1. Amount beneficially owned: The Reporting Person beneficially owns 534,110 shares of VAPO common stock, which includes (a) 390,942 shares of VAPO common stock held directly by the Reporting Person; (b) 42,928 shares of VAPO common stock issuable within 60 days of September 14, 2023 upon exercise of stock options held by the Reporting Person; (c) 59,523 shares of common stock issuable upon exercise of a warrant held by the Reporting Person; (d) 40,625 shares of common stock held by the Kimberly D. Army Revocable Trust; (e) 62 shares of VAPO common stock and 30 shares of VAPO common stock issuable upon exercise of stock options held by the Reporting Person’s spouse. The Reporting Person has sole voting and dispositive power over such shares, except for the shares held by the Kimberly D. Army Revocable Trust and the Reporting Person’s spouse, of which he shares voting and dispositive power.

    2. Percent of class: 8.6%, as of September 14, 2023, based on 6,135,452 shares of VAPO common stock as outstanding as of September 14, 2023.

    (b) Number of shares as to which the reporting person has:

     

    (i)

       Sole power to vote or to direct the vote      493,393  

    (ii)

       Shared power to vote or to direct the vote      40,717  

    (iii)

       Sole power to dispose or to direct the disposition of      493,393  

    (iv)

       Shared power to dispose or to direct the disposition of      40,717  

    (c) Other than the open market purchases effected from August 11, 2023 to September 8, 2023 as reported in this Amendment No. 1, the Reporting Person has not effected any other transactions in VAPO common stock during the past 60 days.

    (d) To the knowledge of the Reporting Person, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of VAPO common stock beneficially owned by the Reporting Person.

    (e) Not applicable.

     

    Item 6.

    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    The Reporting Person, together with certain other holders of VAPO common stock, is a party to a Tenth Amended and Restated Registration Rights Agreement with VAPO which imposes certain affirmative obligations on VAPO and also grants certain rights to the holders, including certain registration rights with respect to the registrable securities held by them, and which agreement was filed as Exhibit 99.1 to the Original Statement.

    The Reporting Person, together with certain other holders of VAPO common stock, is a party to a Securities Purchase Agreement dated February 7, 2023 with VAPO. The Reporting Person also holds a warrant to purchase 59,523 shares of VAPO common stock at an exercise price of $9.36 per share. The Securities Purchase Agreement and a form of warrant agreement representing this warrant is filed as Exhibits 99.1 and 99.2, respectively, to this Amendment No. 1.

     

    Page 5 of 7


    The Reporting Person holds stock options to purchase an aggregate of 46,210 shares of VAPO common stock at exercise prices ranging between $97.28 and $214.88 per share, restricted stock units covering an aggregate of 1,154 shares of VAPO common stock, and performance stock units covering 19,917 shares of VAPO common stock, assuming target performance. In addition, the spouse of the Reporting Person holds stock options to purchase an aggregate of 30 shares of VAPO common stock at exercise prices ranging between $13.44 and $137.20 per share. The equity plan under which these equity awards have been granted and the form of award agreements representing these equity awards were previously filed as Exhibits 99.2, 99.3, 99.4, 99.5 and 99.6 to the Original Statement.

    Except as described herein, there are no other contracts, arrangements, understandings or relationships between the Reporting Person and any other person with respect to any securities of VAPO.

     

    Item 7.

    Material to be Filed as Exhibits.

     

    Exhibit   

    Description

    99.1    Securities Purchase Agreement, dated as of February  7, 2023, among Vapotherm, Inc. and each Purchaser party thereto (previously filed as Exhibit 10.1 to the Current Report on Form 8-K filed on February 8, 2023 (File No. 001-38740) and incorporated herein by reference).
    99.2    Form of Warrant to Purchase Common Stock, dated February  10, 2023, issued by Vapotherm, Inc. in Connection with February 2023 Private Placement (previously filed as Exhibit 4.1 to the Current Report on Form 8-K filed on February 8, 2023 (File No. 001-38740) and incorporated herein by reference).

     

    Page 6 of 7


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: September 20, 2023

     

    /s/ Joseph F. Army
    Joseph F. Army

     

    Page 7 of 7

    Get the next $VAPO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VAPO

    DatePrice TargetRatingAnalyst
    5/6/2022$12.00 → $5.00Buy → Hold
    Canaccord Genuity
    4/7/2022$23.00 → $8.00Overweight → Underweight
    Piper Sandler
    More analyst ratings

    $VAPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Arnerich Anthony L. bought $117,337 worth of shares (37,750 units at $3.11), increasing direct ownership by 263% to 24,509 units (SEC Form 4) (Amendment)

    4/A - VAPOTHERM INC (0001253176) (Issuer)

    10/4/23 4:11:34 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vapotherm Announces Closing of Merger

    EXETER, N.H., Sept. 20, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has closed its merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC. On June 17, 2024, the Company announced that it had signed a definitive agreement and plan of merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund. Concurrently with the entry into the definitive agreem

    9/20/24 10:33:00 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Vapotherm Reports Second Quarter 2024 Financial Results

    EXETER, N.H., Aug. 12, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), today announced second quarter 2024 financial results and related highlights. Second Quarter 2024 Financial Results and Related Highlights Net revenue for the second quarter of 2024 was $16.9 million, an increase of 5.3% as compared to the second quarter of 2023Disposables revenue increased by 13.9% as compared to the second quarter of 2023U.S. disposables revenue increased by 25.9% as compared to the second quarter of 2023Gross margin in the second quarter of 2024 was 49.

    8/12/24 5:15:00 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Vapotherm Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private

    EXETER, N.H., June 17, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has signed a definitive merger agreement with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund.  Concurrently with the entry into the definitive merger agreement, our existing lender, investment affiliates managed by SLR Capital Partners ("SLR") have agreed to convert approximately $81.0 million of term debt into preferred equity of the newly-formed entity, and Perceptive will invest $50.0 million of new preferred equity capital into the b

    6/17/24 6:55:00 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vapotherm downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Vapotherm from Buy to Hold and set a new price target of $5.00 from $12.00 previously

    5/6/22 7:28:09 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Vapotherm downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Vapotherm from Overweight to Underweight and set a new price target of $8.00 from $23.00 previously

    4/7/22 7:25:32 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Piper Sandler reiterated coverage on Vapotherm with a new price target

    Piper Sandler reiterated coverage of Vapotherm with a rating of Overweight and set a new price target of $36.00 from $39.00 previously

    2/25/21 7:36:13 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Arnerich Anthony L. returned $344,305 worth of shares to the company (232,993 units at $1.48), closing all direct ownership in the company (SEC Form 4)

    4 - VAPOTHERM INC (0001253176) (Issuer)

    9/24/24 5:01:08 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    President and CEO Army Joseph returned $43,419 worth of shares to the company (452,698 units at $0.10), closing all direct ownership in the company (SEC Form 4)

    4 - VAPOTHERM INC (0001253176) (Issuer)

    9/24/24 4:43:19 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    SVP & Chief Financial Officer Landry John returned $51,982 worth of shares to the company (71,661 units at $0.73), closing all direct ownership in the company (SEC Form 4)

    4 - VAPOTHERM INC (0001253176) (Issuer)

    9/24/24 4:14:26 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    SEC Filings

    View All

    SEC Form 15-12G filed by Vapotherm Inc.

    15-12G - VAPOTHERM INC (0001253176) (Filer)

    9/25/24 11:32:00 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Vapotherm Inc.

    EFFECT - VAPOTHERM INC (0001253176) (Filer)

    9/25/24 12:15:03 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Vapotherm Inc.

    EFFECT - VAPOTHERM INC (0001253176) (Filer)

    9/25/24 12:15:04 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    Financials

    Live finance-specific insights

    View All

    Vapotherm To Report Second Quarter 2023 Financial Results

    Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors

    7/25/23 4:30:00 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Vapotherm Reports First Quarter 2023 Financial Results

    Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2023 financial results. First Quarter 2023 Summary and Highlights Total revenue for the first quarter of 2023 was $17.7 million Capital revenue increased by 28% as compared to the fourth quarter of 2022 due to strong HVT 2.0 sales Disposables revenue decreased by 12% as compared to the fourth quarter of 2022 due to the timing of the US flu season Gross margin in the first quarter of 2023 was 35.0% Gross margin increased by 750 basis points over the fourth quarter of 2022 due to initial benefits from the transition of operations to Mexico For the first quarter of 2023, GAAP oper

    5/3/23 4:10:00 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Vapotherm To Report First Quarter 2023 Financial Results

    Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the first quarter of 2023 after the close of trading on Wednesday, May 3, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.v

    4/27/23 4:30:00 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    $VAPO
    Leadership Updates

    Live Leadership Updates

    View All

    Perimeter Medical Imaging AI Strengthens Leadership Team with Appointment of Experienced MedTech Executive, Adam Hodges, as Vice President, Sales and Marketing

    TORONTO and DALLAS, Sept. 8, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today announced the appointment of experienced medtech sales executive, Adam Hodges, as its Vice President, Sales and Marketing, effective immediately. Adrian Mendes, Perimeter's Chief Executive Officer stated, "I am excited to welcome Adam to the Perimeter team as our senior leader responsible for the strategy and execution of our sales-related goals. Adam's extensive medtech b

    9/8/23 8:30:00 AM ET
    $IART
    $VAPO
    Medical/Dental Instruments
    Health Care

    Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

    SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

    12/7/22 4:05:00 PM ET
    $EAR
    $ITGR
    $VAPO
    Medical Specialities
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    $VAPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.

    SC 13D/A - VAPOTHERM INC (0001253176) (Subject)

    9/24/24 7:04:57 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.

    SC 13D/A - VAPOTHERM INC (0001253176) (Subject)

    9/20/24 10:32:59 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Vapotherm Inc.

    SC 13G - VAPOTHERM INC (0001253176) (Subject)

    7/18/24 7:24:17 PM ET
    $VAPO
    Medical/Dental Instruments
    Health Care